Medivation, Inc.
http://www.medivation.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medivation, Inc.
Sanfilippo Syndrome Patients, Drug Developers At Odds With US FDA Guidance
Agency recommendation for randomized controlled trials in ultra-rare pediatric disease is unworkable for various reasons, say advocates and sponsors who seek use of the accelerated approval pathway based on changes in heparan sulfate levels.
Riding US Approval, Junshi, Coherus Swing For PD-1 Combo Therapy Partnerships
Antibodies targeting TIGIT, IL-27, CCR8 and BTLA from the Chinese and US firms are among the first batch of combination candidates expected to expand the indications of anti-PD-1 antibody Loqtorzi beyond the rare condition of nasopharyngeal carcinoma.
Lebrikizumab Among Nine Drugs To Get EMA Nod; PTC Faces Disappointment For Translarna
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
Potential Blockbuster Lebrikizumab Among Latest Drugs Up For Decision On EU Approval
The European Medicines Agency is set to decide whether to back EU marketing approval for eight new drugs.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice